Acalabrutinib + Pembrolizumab
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Follicular Lymphoma (FL)
Conditions
Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia
Trial Timeline
Feb 20, 2015 → Oct 27, 2025
NCT ID
NCT02362035About Acalabrutinib + Pembrolizumab
Acalabrutinib + Pembrolizumab is a phase 1/2 stage product being developed by Merck for Follicular Lymphoma (FL). The current trial status is completed. This product is registered under clinical trial identifier NCT02362035. Target conditions include Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL).
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02362035 | Phase 1/2 | Completed |
Competing Products
20 competing products in Follicular Lymphoma (FL)